Selective C-reactive protein apheresis in ST-elevation myocardial infarction: Design and rationale of the randomized CRP-STEMI trial.
Sebastian J Reinstadler, Andreas Kronbichler, Martin Reindl...
https://pubmed.ncbi.nlm.nih.gov/40738310/Actively Recruiting
Led by Medical University Innsbruck · Updated on 2026-10-07
202
Participants Needed
5
Research Sites
45 weeks
Total Duration
Researchers are studying patients who have had an acute ST-elevation myocardial infarction STEMI, a type of heart attack. The study evaluates a new treatment called selective C-reactive protein CRP apheresis, which is being assessed alongside standard care to see if it can reduce the size of the heart damage caused by the heart attack. This clinical trial is a randomized, controlled study aiming to provide evidence on the effectiveness of this treatment. Participants will receive selective CRP apheresis using the PentraSorb-CRP system on the first three days after undergoing primary percutaneous coronary intervention PCI, a procedure to open blocked heart arteries. The study compares this treatment plus standard care to standard care alone. The trial uses a two-group design and is conducted at multiple centers. During the study, participants will be closely monitored with various assessments, including cardiac magnetic resonance imaging CMR at baseline, 4 months, and 12 months after PCI. Researchers will measure heart function, infarct size, inflammation markers, and heart rhythm features. Safety is tracked during hospitalization, and follow-up continues for up to 12 months to record events like heart failure or mortality. The total participation lasts at least one year after treatment.
CONDITIONS
CRP Apheresis in STEMI
S
Sebastian J Reinstadler, MD, PhD
I
Ivan Lechner, MD, PhD
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Medical University Innsbruck
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - 3 days
Participants receive selective CRP apheresis using the PentraSorb®-CRP system on days 1, 2, and 3 after their primary PCI procedure or receive standard care according to guidelines.
3 treatment sessions
Duration - 12 months
Participants undergo cardiac magnetic resonance imaging and other assessments at baseline, 4 months, and 12 months after PCI to monitor heart function and outcomes.
3 visits for imaging and assessments
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Sebastian J Reinstadler, Andreas Kronbichler, Martin Reindl...
https://pubmed.ncbi.nlm.nih.gov/40738310/Medical University Innsbruck
Lead Sponsor